AstraZeneca Plc said the company’s asthma treatment Fasenra for a chronic inflammatory disease of the nasal passage linings, or sinuses, met main goals in a late-stage study.

Drugmakers Sanofi and Regeneron received positive results for Dupixent, which treats eczema and is seen as a key driver of future revenues.

Lyra Therapeutics Inc., a clinical-stage biotechnology company developing medicines precisely designed to target ear, nose and throat (ENT) diseases, announced a $29.5 million Series B equity financing.